beta

DERM

Dermira Inc.

Derm

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

02-26-2019 after market close 11-07-2018 after market close 08-06-2018 05-03-2018 02-22-2018 11-06-2017 08-07-2017 after market close 05-08-2017
Actual EPS -1.7 -1.58 -0.57 -1.39 -1.34 -1.21 -0.93 -0.79
Consensus EPS -1.76 -1.98 -0.57 -1.29 -1.25 -1.12 -0.85 -0.86
Estimated EPS -1.76 -1.98 -0.57 -1.29 -1.25 -1.12 -0.85 -0.86
Number of Estimates 3 1 1 2 2 2 2 2
EPS Surprise $0.06 $0.40 -$0.10 -$0.09 -$0.09 -$0.08 $0.07

Stats

Summary

Dermira Inc is a biopharmaceutical company. It is engaged in identifying, developing and commercializing therapies to improve the lives of patients with dermatologic diseases.

Market Cap: 1.26 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.dermira.com

Shares Outstanding: 41.7 Million

Float: 41.5 Million

Dividend: 0.0 (0.0%)

Beta: 0.845965

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 3.94 Million

Ethical Flags

Animal testing

Longest drawdown: 575 trading days

From: 2017-03-06 To: 2019-06-12

Lowest Point:

Dermira to Present at the Raymond James Life Sciences and MedTech Conference

via: Business Wire at 2019-06-11 12:00:00:000

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present at the Ra… read more...

Dermira to Present at the Raymond James Life Sciences and MedTech Conference

via: Business Wire at 2019-06-11 12:00:00:000

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present at the Ra… read more...

Dermira to Present at the Raymond James Life Sciences and MedTech Conference

via: Business Wire at 2019-06-11 12:00:00:000

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present at the Ra… read more...

Dermira, Inc. (DERM) CEO Tom Wiggans on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-07 18:31:16:000

Dermira, Inc. (DERM) Q1 2019 Earnings Conference Call May 07, 2019, 04:30 PM ET Company Participants Andrew Guggenhime - CFO Tom Wiggans - Founder, Chairman, and CEO Lori Lyons-Williams - CCO Luis Pea - CDO Conference Call Participants Louise Chen - Cantor Serge B… read more...

Dermira, Inc. (DERM) CEO Tom Wiggans on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-07 18:31:16:000

Dermira, Inc. (DERM) Q1 2019 Earnings Conference Call May 07, 2019, 04:30 PM ET Company Participants Andrew Guggenhime - CFO Tom Wiggans - Founder, Chairman, and CEO Lori Lyons-Williams - CCO Luis Pea - CDO Conference Call Participants Louise Chen - Cantor Serge B… read more...

Dermira, Inc. (DERM) CEO Tom Wiggans on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-07 18:31:16:000

Dermira, Inc. (DERM) Q1 2019 Earnings Conference Call May 07, 2019, 04:30 PM ET Company Participants Andrew Guggenhime - CFO Tom Wiggans - Founder, Chairman, and CEO Lori Lyons-Williams - CCO Luis Pea - CDO Conference Call Participants Louise Chen - Cantor Serge B… read more...

Dermira beats by $0.12, misses on revenue

via: SeekingAlpha at 2019-05-07 12:19:05:000

Dermira (NASDAQ: DERM ): Q1 GAAP EPS of -$1.49 beats by $0.12 . Revenue of $2.45M misses by $0.19M . Press Release More news on: Dermira, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update

via: Business Wire at 2019-05-07 12:05:00:000

QBREXZA (glycopyrronium) cloth prescriptions increased more than 50% over fourth quarter 2018 First quarter net product sales of $2.5 million Approximately 80% of commercially insured patients have access to QBREXZA End-of-Phase 2 FDA meeting scheduled following … read more...

Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019

via: Business Wire at 2019-04-30 12:05:00:000

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report financial results for the quarter ended March 31, 20… read more...

Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019

via: Business Wire at 2019-04-30 12:05:00:000

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report financial results for the quarter ended March 31, 20… read more...

Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019

via: Business Wire at 2019-04-30 12:05:00:000

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report financial results for the quarter ended March 31, 20… read more...

Market At New Highs, But Healthcare And Biotechs Feel The Heat

via: SeekingAlpha at 2019-04-29 09:22:32:000

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m… read more...

Dermira to Present at the 18th Annual Needham Healthcare Conference

via: Business Wire at 2019-04-03 12:05:00:000

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a … read more...

Dermira to Present at the 18th Annual Needham Healthcare Conference

via: Business Wire at 2019-04-03 12:05:00:000

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a … read more...

Dermira to Present at the 18th Annual Needham Healthcare Conference

via: Business Wire at 2019-04-03 12:05:00:000

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a … read more...

Dermira prices stock offering

via: SeekingAlpha at 2019-03-20 01:40:16:000

Dermira ( DERM ) prices public offering of 9.81M common shares at $13.25/share for gross proceeds of ~$130M. More news on: Dermira, Inc., Read more … read more...

Dermira prices stock offering

via: SeekingAlpha at 2019-03-20 01:40:16:000

Dermira ( DERM ) prices public offering of 9.81M common shares at $13.25/share for gross proceeds of ~$130M. More news on: Dermira, Inc., Read more … read more...

Dermira prices stock offering

via: SeekingAlpha at 2019-03-20 01:40:16:000

Dermira ( DERM ) prices public offering of 9.81M common shares at $13.25/share for gross proceeds of ~$130M. More news on: Dermira, Inc., Read more … read more...

Dermira readies $110M equity offering

via: SeekingAlpha at 2019-03-19 02:32:52:000

Dermira (NASDAQ: DERM ) intends to offer $110M common stock in a public offering. More news on: Dermira, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Healthcare names top midday movers

via: SeekingAlpha at 2019-03-18 08:46:44:000

Gainers: Dermira (NASDAQ: DERM ) +85% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +48% . Atossa Genetics (NASDAQ: ATOS ) +35% . American Midstream Partners (NYSE: AMID ) +28% . Aclaris Therapeutics (NASDAQ: ACRS ) +21% . Innovate Biopharmaceuticals (NASDAQ: INNT ) +20% . Profess… read more...

RIOT, PXLW and ATOS among premarket gainers

via: SeekingAlpha at 2019-03-18 05:25:53:000

PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +108% on positive PB2452 data . More news on: PhaseBio Pharmaceuticals, Inc., Dermira, Inc., Leap Therapeutics, Inc., Stocks on the move, Read more … read more...

Dermira up 74% premarket on positive lebrikizumab data

via: SeekingAlpha at 2019-03-18 03:51:53:000

Dermira (NASDAQ: DERM ) is up 74% premarket on average volume in response to successful result s from a Phase 2b dose-ranging study of lebrikizumab in patients with moderate-to-severe atopic dermatitis (AD). More news on: Dermira, Inc., Healthcare stocks news, Stocks on the … read more...

GME, NVTA, PS and SOI among after hours movers

via: SeekingAlpha at 2019-03-04 12:34:34:000

Gainers: OTIC +5.5% . DERM +4.9% . GME +3.9% . SOI +3.2% . CTBB +3.1% . More news on: Otonomy, Dermira, GameStop Corp., Stocks on the move, Read more … read more...

GME, NVTA, PS and SOI among after hours movers

via: SeekingAlpha at 2019-03-04 12:34:34:000

Gainers: OTIC +5.5% . DERM +4.9% . GME +3.9% . SOI +3.2% . CTBB +3.1% . More news on: Otonomy, Dermira, GameStop Corp., Stocks on the move, Read more … read more...

GME, NVTA, PS and SOI among after hours movers

via: SeekingAlpha at 2019-03-04 12:34:34:000

Gainers: OTIC +5.5% . DERM +4.9% . GME +3.9% . SOI +3.2% . CTBB +3.1% . More news on: Otonomy, Dermira, GameStop Corp., Stocks on the move, Read more … read more...

Dermira (DERM) CEO Tom Wiggans on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-26 23:22:04:000

Morgan Stanley (MS) Q4 2018 Results Earnings Conference Call February 26, 2019, 04:30 PM ET Company Participants Ian Clements - IR Thomas Wiggans - Founder, Chairman, and CEO Lori Lyons-Williams - CCO Luis Pea - CDO Andrew Guggenhime - CFO Conference Call Participant… read more...

Dermira (DERM) CEO Tom Wiggans on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-26 23:22:04:000

Morgan Stanley (MS) Q4 2018 Results Earnings Conference Call February 26, 2019, 04:30 PM ET Company Participants Ian Clements - IR Thomas Wiggans - Founder, Chairman, and CEO Lori Lyons-Williams - CCO Luis Pea - CDO Andrew Guggenhime - CFO Conference Call Participant… read more...

Dermira (DERM) CEO Tom Wiggans on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-26 18:22:04:000

Morgan Stanley (MS) Q4 2018 Results Earnings Conference Call February 26, 2019, 04:30 PM ET Company Participants Ian Clements - IR Thomas Wiggans - Founder, Chairman, and CEO Lori Lyons-Williams - CCO Luis Pea - CDO Andrew Guggenhime - CFO Conference Call Participant… read more...

Dermira beats by $0.45, beats on revenue

via: SeekingAlpha at 2019-02-26 16:06:08:000

Dermira (NASDAQ: DERM ): Q4 GAAP EPS of -$1.70 beats by $0.45 . Revenue of $2.24M (+67.2% Y/Y) beats by $1M . Press Release More news on: Dermira, Earnings news and commentary, Healthcare stocks news, read more...

Dermira launches study evaluating QBREXZA cloth; shares up 2% premarket

via: SeekingAlpha at 2019-02-22 08:43:47:000

Dermira (NASDAQ: DERM ) has initiated a proof-of-concept study that will evaluate the efficacy and safety of QBREXZA (glycopyrronium) cloth in people with primary palmar hyperhidrosis (excessive sweating of the hands). More news on: Dermira, Healthcare stocks news, Stocks on the move, … read more...

Dermira launches study evaluating QBREXZA cloth; shares up 2% premarket

via: SeekingAlpha at 2019-02-22 08:43:47:000

Dermira (NASDAQ: DERM ) has initiated a proof-of-concept study that will evaluate the efficacy and safety of QBREXZA (glycopyrronium) cloth in people with primary palmar hyperhidrosis (excessive sweating of the hands). More news on: Dermira, Healthcare stocks news, Stocks on the move, … read more...

Dermira launches study evaluating QBREXZA cloth; shares up 2% premarket

via: SeekingAlpha at 2019-02-22 08:43:47:000

Dermira (NASDAQ: DERM ) has initiated a proof-of-concept study that will evaluate the efficacy and safety of QBREXZA (glycopyrronium) cloth in people with primary palmar hyperhidrosis (excessive sweating of the hands). More news on: Dermira, Healthcare stocks news, Stocks on the move, … read more...

Dermira launches study evaluating QBREXZA cloth; shares up 2% premarket

via: SeekingAlpha at 2019-02-22 08:43:47:000

Dermira (NASDAQ: DERM ) has initiated a proof-of-concept study that will evaluate the efficacy and safety of QBREXZA (glycopyrronium) cloth in people with primary palmar hyperhidrosis (excessive sweating of the hands). More news on: Dermira, Healthcare stocks news, Stocks on the move, … read more...

Nomura bearish on Xencor in premarket analyst action

via: SeekingAlpha at 2019-02-22 07:40:50:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Nomura bearish on Xencor in premarket analyst action

via: SeekingAlpha at 2019-02-22 07:40:50:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Nomura bearish on Xencor in premarket analyst action

via: SeekingAlpha at 2019-02-22 07:40:50:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Nomura bearish on Xencor in premarket analyst action

via: SeekingAlpha at 2019-02-22 07:40:50:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Dermira enters into credit facility with Athyrium Capital Management

via: SeekingAlpha at 2018-12-04 08:24:06:000

Dermira (NASDAQ: DERM ) closes a $125M credit facility with funds managed by Athyrium Capital Management, LP. More news on: Dermira, Healthcare stocks news, Read more … read more...

Dermira enters into credit facility with Athyrium Capital Management

via: SeekingAlpha at 2018-12-04 08:24:06:000

Dermira (NASDAQ: DERM ) closes a $125M credit facility with funds managed by Athyrium Capital Management, LP. More news on: Dermira, Healthcare stocks news, Read more … read more...

Dermira enters into credit facility with Athyrium Capital Management

via: SeekingAlpha at 2018-12-04 08:24:06:000

Dermira (NASDAQ: DERM ) closes a $125M credit facility with funds managed by Athyrium Capital Management, LP. More news on: Dermira, Healthcare stocks news, Read more … read more...

Dermira enters into credit facility with Athyrium Capital Management

via: SeekingAlpha at 2018-12-04 08:24:06:000

Dermira (NASDAQ: DERM ) closes a $125M credit facility with funds managed by Athyrium Capital Management, LP. More news on: Dermira, Healthcare stocks news, Read more … read more...

Dermira (DERM) CEO Tom Wiggans on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-07 20:05:05:000

Dermira (DERM) Q3 2018 Earnings Conference Call November 7, 2018 4:30 p.m. ET Executives Ian Clements - IR Tom Wiggans - Chairman and CEO Lori Lyons-Williams - Chief Commercial Officer Luis Pena - Chief Development Officer Andrew Guggenhime - CFO Analysts Louise Chen - … read more...

Dermira (DERM) CEO Tom Wiggans on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-07 20:05:05:000

Dermira (DERM) Q3 2018 Earnings Conference Call November 7, 2018 4:30 p.m. ET Executives Ian Clements - IR Tom Wiggans - Chairman and CEO Lori Lyons-Williams - Chief Commercial Officer Luis Pena - Chief Development Officer Andrew Guggenhime - CFO Analysts Louise Chen - … read more...

Dermira (DERM) CEO Tom Wiggans on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-07 20:05:05:000

Dermira (DERM) Q3 2018 Earnings Conference Call November 7, 2018 4:30 p.m. ET Executives Ian Clements - IR Tom Wiggans - Chairman and CEO Lori Lyons-Williams - Chief Commercial Officer Luis Pena - Chief Development Officer Andrew Guggenhime - CFO Analysts Louise Chen - … read more...

Dermira beats by $0.05, beats on revenue

via: SeekingAlpha at 2018-11-07 17:18:47:000

Dermira (NASDAQ: DERM ): Q3 GAAP EPS of -$1.58 beats by $0.05 . Revenue of $0.7M (-34.6% Y/Y) beats by $0.25M . Press Release More news on: Dermira, Earnings news and commentary, Healthcare stocks news, read more...

Dermira's QBREXZA cloth is now available in pharmacies nationwide for the treatment of primary axillary hyperhidrosis

via: SeekingAlpha at 2018-10-01 09:20:35:000

Dermira (NASDAQ: DERM ) announces that QBREXZA (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis, commonly known as excessive underarm sweating. The new therapy is available in retail and community pharmacies nationwide. More news on: Dermira… read more...

Dermira's QBREXZA cloth is now available in pharmacies nationwide for the treatment of primary axillary hyperhidrosis

via: SeekingAlpha at 2018-10-01 09:20:35:000

Dermira (NASDAQ: DERM ) announces that QBREXZA (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis, commonly known as excessive underarm sweating. The new therapy is available in retail and community pharmacies nationwide. More news on: Dermira… read more...

Dermira's QBREXZA cloth is now available in pharmacies nationwide for the treatment of primary axillary hyperhidrosis

via: SeekingAlpha at 2018-10-01 09:20:35:000

Dermira (NASDAQ: DERM ) announces that QBREXZA (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis, commonly known as excessive underarm sweating. The new therapy is available in retail and community pharmacies nationwide. More news on: Dermira… read more...

Dermira provides launch update for QBREXZA cloth for primary axillary hyperhidrosis

via: SeekingAlpha at 2018-09-05 08:41:41:000

Dermira, Inc. (NASDAQ: DERM ) announces several updates related to the upcoming launch and availability of QBREXZA (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. QBRE… read more...

Dermira provides launch update for QBREXZA cloth for primary axillary hyperhidrosis

via: SeekingAlpha at 2018-09-05 08:41:41:000

Dermira, Inc. (NASDAQ: DERM ) announces several updates related to the upcoming launch and availability of QBREXZA (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. QBRE… read more...

Dermira provides launch update for QBREXZA cloth for primary axillary hyperhidrosis

via: SeekingAlpha at 2018-09-05 08:41:41:000

Dermira, Inc. (NASDAQ: DERM ) announces several updates related to the upcoming launch and availability of QBREXZA (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. QBRE… read more...

Dermira misses by $0.06, misses on revenue

via: SeekingAlpha at 2018-08-06 16:53:17:000

Dermira (NASDAQ: DERM ): Q2 EPS of -$0.57 misses by $0.06 . Revenue of $39.1M (+3554.2% Y/Y) misses by $0.1M . Press Release More news on: Dermira, Earnings news and commentary, Healthcare stocks news, read more...

Dermira misses by $0.06, misses on revenue

via: SeekingAlpha at 2018-08-06 16:53:17:000

Dermira (NASDAQ: DERM ): Q2 EPS of -$0.57 misses by $0.06 . Revenue of $39.1M (+3554.2% Y/Y) misses by $0.1M . Press Release More news on: Dermira, Earnings news and commentary, Healthcare stocks news, read more...

Dermira misses by $0.06, misses on revenue

via: SeekingAlpha at 2018-08-06 16:53:17:000

Dermira (NASDAQ: DERM ): Q2 EPS of -$0.57 misses by $0.06 . Revenue of $39.1M (+3554.2% Y/Y) misses by $0.1M . Press Release More news on: Dermira, Earnings news and commentary, Healthcare stocks news, read more...

Insider Weekends - Chairman Of Trucking Company Buys Shares Under A 10b5-1 Purchase Plan

via: SeekingAlpha at 2018-07-16 07:49:57:000

Insider buying decreased significantly last week with insiders purchasing $20.33 million of stock compared to $220.22 million in the week prior. Selling, on the other hand, increased with insiders selling $937.49 million of stock last week compared to $823.77 million in the week prior. The per… read more...

Insider Weekends - Chairman Of Trucking Company Buys Shares Under A 10b5-1 Purchase Plan

via: SeekingAlpha at 2018-07-16 07:49:57:000

Insider buying decreased significantly last week with insiders purchasing $20.33 million of stock compared to $220.22 million in the week prior. Selling, on the other hand, increased with insiders selling $937.49 million of stock last week compared to $823.77 million in the week prior. The per… read more...

Insider Weekends - Chairman Of Trucking Company Buys Shares Under A 10b5-1 Purchase Plan

via: SeekingAlpha at 2018-07-16 07:49:57:000

Insider buying decreased significantly last week with insiders purchasing $20.33 million of stock compared to $220.22 million in the week prior. Selling, on the other hand, increased with insiders selling $937.49 million of stock last week compared to $823.77 million in the week prior. The per… read more...

Dermira May Provide Some Upside Potential, Even After Latest FDA Approval

via: SeekingAlpha at 2018-07-02 05:29:10:000

Recently, Dermira ( DERM ) announced that it had received FDA approval for its drug Qbrexza to treat patients with Primary axillary hyperhidrosis. This latest FDA approval is the start of a turnaround for the company, but there is something else in the pipeline that could turn things aro… read more...

Dermira May Provide Some Upside Potential, Even After Latest FDA Approval

via: SeekingAlpha at 2018-07-02 05:29:10:000

Recently, Dermira ( DERM ) announced that it had received FDA approval for its drug Qbrexza to treat patients with Primary axillary hyperhidrosis. This latest FDA approval is the start of a turnaround for the company, but there is something else in the pipeline that could turn things aro… read more...

Dermira May Provide Some Upside Potential, Even After Latest FDA Approval

via: SeekingAlpha at 2018-07-02 05:29:10:000

Recently, Dermira ( DERM ) announced that it had received FDA approval for its drug Qbrexza to treat patients with Primary axillary hyperhidrosis. This latest FDA approval is the start of a turnaround for the company, but there is something else in the pipeline that could turn things aro… read more...

Evercore sees big market for new Dermira drug; shares +5.5%

via: SeekingAlpha at 2018-06-29 11:02:09:000

Dermira (NASDAQ: DERM ) is up 5.5% , with Evercore seeing solid market opportunity after the company's prescription wipe for excessive underarm sweat won FDA approval . More news on: Dermira, Healthcare stocks news, Stocks on the move, Read more … read more...

Evercore sees big market for new Dermira drug; shares +5.5%

via: SeekingAlpha at 2018-06-29 11:02:09:000

Dermira (NASDAQ: DERM ) is up 5.5% , with Evercore seeing solid market opportunity after the company's prescription wipe for excessive underarm sweat won FDA approval . More news on: Dermira, Healthcare stocks news, Stocks on the move, Read more … read more...

Evercore sees big market for new Dermira drug; shares +5.5%

via: SeekingAlpha at 2018-06-29 11:02:09:000

Dermira (NASDAQ: DERM ) is up 5.5% , with Evercore seeing solid market opportunity after the company's prescription wipe for excessive underarm sweat won FDA approval . More news on: Dermira, Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (6/29/2018)

via: SeekingAlpha at 2018-06-29 09:15:58:000

GEMP +114% asGemcabene drug candidate met its primary endpoint . More news on: Gemphire Therapeutics, Echelon Corporation, Dermira, News on the U.S. economy, Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (6/29/2018)

via: SeekingAlpha at 2018-06-29 09:15:58:000

GEMP +114% asGemcabene drug candidate met its primary endpoint . More news on: Gemphire Therapeutics, Echelon Corporation, Dermira, News on the U.S. economy, Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (6/29/2018)

via: SeekingAlpha at 2018-06-29 09:15:58:000

GEMP +114% asGemcabene drug candidate met its primary endpoint . More news on: Gemphire Therapeutics, Echelon Corporation, Dermira, News on the U.S. economy, Stocks on the move, Read more … read more...

Dermira wins FDA nod for underarm sweating treatment

via: SeekingAlpha at 2018-06-29 07:19:40:000

The FDA has approved Qbrexza(glycopyrronium) cloth, the first once-daily, topical prescription treatment forprimary axillary hyperhidrosis, otherwise known as excessive underarm sweating. More news on: Dermira, Healthcare stocks news, Read more … read more...

Dermira wins FDA nod for underarm sweating treatment

via: SeekingAlpha at 2018-06-29 07:19:40:000

The FDA has approved Qbrexza(glycopyrronium) cloth, the first once-daily, topical prescription treatment forprimary axillary hyperhidrosis, otherwise known as excessive underarm sweating. More news on: Dermira, Healthcare stocks news, Read more … read more...

Dermira wins FDA nod for underarm sweating treatment

via: SeekingAlpha at 2018-06-29 07:19:40:000

The FDA has approved Qbrexza(glycopyrronium) cloth, the first once-daily, topical prescription treatment forprimary axillary hyperhidrosis, otherwise known as excessive underarm sweating. More news on: Dermira, Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-21 15:28:40:000

Noteworthy events during the week of June 24 - 30 for healthcare investors. More news on: Roche Holding Ltd ADR, Achaogen, Pain Therapeutics, Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-21 15:28:40:000

Noteworthy events during the week of June 24 - 30 for healthcare investors. More news on: Roche Holding Ltd ADR, Achaogen, Pain Therapeutics, Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-21 15:28:40:000

Noteworthy events during the week of June 24 - 30 for healthcare investors. More news on: Roche Holding Ltd ADR, Achaogen, Pain Therapeutics, Healthcare stocks news, Read more … read more...

Dermira (DERM) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-05-25 14:48:55:000

The following slide deck was published by Dermira in conjunction with this Read more … read more...

Dermira (DERM) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-05-25 14:48:55:000

The following slide deck was published by Dermira in conjunction with this Read more … read more...

Dermira (DERM) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-05-25 14:48:55:000

The following slide deck was published by Dermira in conjunction with this Read more … read more...

Dermira (DERM) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-05-25 14:48:55:000

The following slide deck was published by Dermira in conjunction with this Read more … read more...

Dermira (DERM) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-05-25 14:48:55:000

The following slide deck was published by Dermira in conjunction with this Read more … read more...

Dermira (DERM) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-05-25 14:48:55:000

The following slide deck was published by Dermira in conjunction with this Read more … read more...

Dermira (DERM) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-05-25 14:48:55:000

The following slide deck was published by Dermira in conjunction with this Read more … read more...

Dermira Investor Day fails to stoke buying, shares down 15%

via: SeekingAlpha at 2018-05-24 14:16:21:000

Dermira ( DERM -14.7% ) slumps on average volume after the company's investor update earlier today. More news on: Dermira, Healthcare stocks news, Stocks on the move, Read more … read more...

Dermira Investor Day fails to stoke buying, shares down 15%

via: SeekingAlpha at 2018-05-24 14:16:21:000

Dermira ( DERM -14.7% ) slumps on average volume after the company's investor update earlier today. More news on: Dermira, Healthcare stocks news, Stocks on the move, Read more … read more...

Dermira Investor Day fails to stoke buying, shares down 15%

via: SeekingAlpha at 2018-05-24 14:16:21:000

Dermira ( DERM -14.7% ) slumps on average volume after the company's investor update earlier today. More news on: Dermira, Healthcare stocks news, Stocks on the move, Read more … read more...

Dermira Investor Day fails to stoke buying, shares down 15%

via: SeekingAlpha at 2018-05-24 14:16:21:000

Dermira ( DERM -14.7% ) slumps on average volume after the company's investor update earlier today. More news on: Dermira, Healthcare stocks news, Stocks on the move, Read more … read more...

Dermira misses by $0.06, beats on revenue

via: SeekingAlpha at 2018-05-03 16:47:40:000

Dermira (NASDAQ: DERM ): Q1 EPS of -$1.42 misses by $0.06 . More news on: Dermira, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Dermira misses by $0.06, beats on revenue

via: SeekingAlpha at 2018-05-03 16:47:40:000

Dermira (NASDAQ: DERM ): Q1 EPS of -$1.42 misses by $0.06 . More news on: Dermira, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Dermira misses by $0.06, beats on revenue

via: SeekingAlpha at 2018-05-03 16:47:40:000

Dermira (NASDAQ: DERM ): Q1 EPS of -$1.42 misses by $0.06 . More news on: Dermira, Earnings news and commentary, Healthcare stocks news, Read more … read more...

ASLAN Pharmaceuticals Updates U.S. IPO Plans

via: SeekingAlpha at 2018-04-18 17:49:43:000

Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to raise $60.4 million from the sale of ADSs in a U.S. IPO . The company targets cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe. ASLN is making excellent progress on its pipeline o… read more...

ASLAN Pharmaceuticals Updates U.S. IPO Plans

via: SeekingAlpha at 2018-04-18 17:49:43:000

Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to raise $60.4 million from the sale of ADSs in a U.S. IPO . The company targets cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe. ASLN is making excellent progress on its pipeline o… read more...

ASLAN Pharmaceuticals Updates U.S. IPO Plans

via: SeekingAlpha at 2018-04-18 17:49:43:000

Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to raise $60.4 million from the sale of ADSs in a U.S. IPO . The company targets cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe. ASLN is making excellent progress on its pipeline o… read more...

ASLAN Pharmaceuticals Files For $86 Million U.S. IPO

via: SeekingAlpha at 2018-04-06 13:28:03:000

Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to sell ADSs of its common stock for gross proceeds of $86.3 million from a U.S. IPO, according to an F-1 registration statement . The firm is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents a… read more...

ASLAN Pharmaceuticals Files For $86 Million U.S. IPO

via: SeekingAlpha at 2018-04-06 13:28:03:000

Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to sell ADSs of its common stock for gross proceeds of $86.3 million from a U.S. IPO, according to an F-1 registration statement . The firm is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents a… read more...

ASLAN Pharmaceuticals Files For $86 Million U.S. IPO

via: SeekingAlpha at 2018-04-06 13:28:03:000

Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to sell ADSs of its common stock for gross proceeds of $86.3 million from a U.S. IPO, according to an F-1 registration statement . The firm is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents a… read more...

Your first trade for Friday, March 9

via: CNBC at 2018-03-09 09:09:00:000

No summary available. read more...

Your first trade for Friday, March 9

via: CNBC at 2018-03-09 09:09:00:000

No summary available. read more...

Your first trade for Friday, March 9

via: CNBC at 2018-03-09 09:09:00:000

No summary available. read more...

3 Things In Biotech, March 7: Aimmune Scores, Bristol-Myers Compresses, Dermira Bombs

via: SeekingAlpha at 2018-03-08 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech, March 7: Aimmune Scores, Bristol-Myers Compresses, Dermira Bombs

via: SeekingAlpha at 2018-03-08 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech, March 7: Aimmune Scores, Bristol-Myers Compresses, Dermira Bombs

via: SeekingAlpha at 2018-03-08 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

Biotech Forum Daily Digest For March 7th

via: SeekingAlpha at 2018-03-07 09:33:24:000

Love all, trust a few, do wrong to none . William Shakespeare The choppy nature of the market continues. After posting slight gains on Tuesday, the main biotech indices will open substantially down today as will the rest of the overall market. Today's rally killer is t… read more...

Biotech Forum Daily Digest For March 7th

via: SeekingAlpha at 2018-03-07 09:33:24:000

Love all, trust a few, do wrong to none . William Shakespeare The choppy nature of the market continues. After posting slight gains on Tuesday, the main biotech indices will open substantially down today as will the rest of the overall market. Today's rally killer is t… read more...

Biotech Forum Daily Digest For March 7th

via: SeekingAlpha at 2018-03-07 09:33:24:000

Love all, trust a few, do wrong to none . William Shakespeare The choppy nature of the market continues. After posting slight gains on Tuesday, the main biotech indices will open substantially down today as will the rest of the overall market. Today's rally killer is t… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-03-06 08:51:30:000

Athenex (NASDAQ: ATNX ) initiated with Buy rating and $30 (88% upside) price target at Needham. More news on: Athenex, Inc., Insulet Corporation, Becton, Dickinson and Company, Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-03-06 08:51:30:000

Athenex (NASDAQ: ATNX ) initiated with Buy rating and $30 (88% upside) price target at Needham. More news on: Athenex, Inc., Insulet Corporation, Becton, Dickinson and Company, Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-03-06 08:51:30:000

Athenex (NASDAQ: ATNX ) initiated with Buy rating and $30 (88% upside) price target at Needham. More news on: Athenex, Inc., Insulet Corporation, Becton, Dickinson and Company, Healthcare stocks news, Stocks on the move, Read more … read more...

Your Daily Pharma Scoop: Aimmune Data, Onconova Shares Get A Boost, G1 Therapeutics' Positive Data

via: SeekingAlpha at 2018-03-06 08:00:00:000

Analysis of top Seeking Alpha coverage: Aimmune Therapeutics Today we will discuss Aimmune Therapeutics ( AIMT ), which is up sharply after announcing detailed results from the pivotal phase 3 PALISADE trial evaluating its AR101 as a treatment for peanut allergy. Last month, the company h… read more...

Your Daily Pharma Scoop: Aimmune Data, Onconova Shares Get A Boost, G1 Therapeutics' Positive Data

via: SeekingAlpha at 2018-03-06 08:00:00:000

Analysis of top Seeking Alpha coverage: Aimmune Therapeutics Today we will discuss Aimmune Therapeutics ( AIMT ), which is up sharply after announcing detailed results from the pivotal phase 3 PALISADE trial evaluating its AR101 as a treatment for peanut allergy. Last month, the company h… read more...

Your Daily Pharma Scoop: Aimmune Data, Onconova Shares Get A Boost, G1 Therapeutics' Positive Data

via: SeekingAlpha at 2018-03-06 08:00:00:000

Analysis of top Seeking Alpha coverage: Aimmune Therapeutics Today we will discuss Aimmune Therapeutics ( AIMT ), which is up sharply after announcing detailed results from the pivotal phase 3 PALISADE trial evaluating its AR101 as a treatment for peanut allergy. Last month, the company h… read more...

Dermira Tumbles On Phase 3 Data For Acne, But Hope Remains

via: SeekingAlpha at 2018-03-06 07:30:01:000

On Monday, Dermira ( DERM ) announced that it had failed two phase 3 trials using its topical gel olumacostat glasaretil ((DRM01)). Both of these trials were treating patients with acne. It is really bad that the company did not succeed in either study, but that doesn't mean that it is the e… read more...

Dermira Tumbles On Phase 3 Data For Acne, But Hope Remains

via: SeekingAlpha at 2018-03-06 07:30:01:000

On Monday, Dermira ( DERM ) announced that it had failed two phase 3 trials using its topical gel olumacostat glasaretil ((DRM01)). Both of these trials were treating patients with acne. It is really bad that the company did not succeed in either study, but that doesn't mean that it is the e… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: March 5, 2018

via: SeekingAlpha at 2018-03-06 03:38:23:000

U.S. equity indexes extended their uptrend today. Till 24,200 on the Dow Jones Industrial Index holds, we are long equities. ^DJI data by YCharts Investors seemed unimpressed with Sorrento Therapeutics ( SRNE ) release of data from 3 additional patients with liver metastases due to … read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: March 5, 2018

via: SeekingAlpha at 2018-03-06 03:38:23:000

U.S. equity indexes extended their uptrend today. Till 24,200 on the Dow Jones Industrial Index holds, we are long equities. ^DJI data by YCharts Investors seemed unimpressed with Sorrento Therapeutics ( SRNE ) release of data from 3 additional patients with liver metastases due to … read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: Jan. 18, 2018

via: SeekingAlpha at 2018-01-19 12:08:08:000

Market and sector outlook: There has been some market nervousness over the debt ceiling issue. The VIX again rose today and is above 12 level. The 10-bond yield is still rising, extended and ripe for a fall. [[IBB]] and [[XBI]] are likely to make another high to around $116 and $92, resp… read more...

Your Daily Pharma Scoop: Lipocine Ahead Of Ad Com, Ohr's MAKO Study Fails, Zafgen Provides Update

via: SeekingAlpha at 2018-01-06 07:58:38:000

Analysis of top Seeking Alpha coverage: Lipocine Today we will discuss Lipocine ( LPCN ), which fell more than 10% on Friday ahead of the Ad Com for its lead product candidate TLANDO, an oral testosterone replacement therapy ((TRT)). TLANDOs New Drug Application (NDA) was rej… read more...

Your Daily Pharma Scoop: AEterna Zentaris Gets FDA Nod, Valeant Finalizes Sprout Sale, Roche Gets EC Approval

via: SeekingAlpha at 2017-12-21 09:42:09:000

Content Analysis of coverage: AEZS Stocks in the news: Analyst Ratings Insider Sales Insider Purchases Secondary Offerings Earnings Report Earnings Calendar Catalyst Rundown Analysis of top Seeking Alpha coverage: AEterna Zentaris Today we will foc… read more...

Your Daily Pharma Scoop: Right Time To Buy Regeneron, Eli Lilly Gives Guidance, Bluebird Announces Offering

via: SeekingAlpha at 2017-12-14 04:07:55:000

Content Analysis of coverage: REGN Stocks in the news: LLY, SNY, BLUE Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Trade Idea of the Day (for TPT subscribers only) Subscriber Questions & An… read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2017-12-08 17:35:17:000

Top gainers: UTSI +7.6% . FATE +6.5% . OSTK +3.8% . IMDZ +3.8% . VSTM +3.9% . More news on: UTStarcom, Inc., Fate Therapeutics, Inc., Overstock.com, Inc., Stocks on the move, Read more … read more...

ROTY Edition 1 Volume 59: Updates And Trades

via: SeekingAlpha at 2017-12-07 11:37:23:000

Welcome to the 59th entry in our Runner of the Year ((ROTY)) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primar… read more...

Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars

via: SeekingAlpha at 2017-12-07 08:00:00:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2017-12-06 09:12:40:000

Foamix (NASDAQ: FOMX ) initiated with Buy rating and $8 (43% upside) price target by Guggenheim. More news on: Foamix Pharmaceuticals, Revance Therapeutics, Inc., Dermira, Healthcare stocks news, Stocks on the move, Read more … read more...

Dermira: Buy Before Several Catalysts Coming In 2018

via: SeekingAlpha at 2017-12-01 11:09:09:000

Shares of dermatology-focused biotech Dermira ( DERM ) have fallen by around 10% since February when I stated that the company's late-stage assets were undervalued. I also suggested investors keep the ticker on their radar and revisit again after a couple quarters, hence the need for this up… read more...

Dermira (DERM) Presents At Stifel 2017 Healthcare Conference - Slideshow

via: SeekingAlpha at 2017-11-16 14:07:40:000

The following slide deck was published by Dermira in conjunction with this Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX